title: Observations on the use of thrombolytic agents for thrombotic occlusion of infrainguinal vein grafts.
abstract: Vein graft failure remains a major challenge for the vascular surgeon. Thrombolysis of occluded vein grafts has shown promising short-term results in restoring vein graft patency, however, the long-term results are not established. This study examines the long-term patency and limb salvage after successful thrombolysis and revision of 22 thrombosed vein grafts in 21 patients. There were 17 men and four women with an average age of 60 years (38 to 77 years). Failed vein grafts had an average primary patency of 19 months (1 to 84 months) and included eight in situ grafts and 14 non-in situ grafts. Twelve grafts were to the popliteal level, whereas 10 were infrapopliteal. Thrombolytic agents used included urokinase (15), tissue plasminogen activator (5), and streptokinase (2). After successful thrombolysis, 19 grafts underwent 26 additional procedures including percutaneous transluminal angioplasty (9), vein patch angioplasty (4), vein interposition or jump extension graft (9), or other procedures (4). Three patients had no additional procedure, but one was placed on sodium warfarin (Coumadin). After successful initial vein graft salvage, life-table analysis revealed a 36.6% +/- 11.9% patency at 1 year and a 22.9% +/- 11.6% patency at 3 years. After secondary failure six patients had further interventions contributing to an improved limb salvage of 66.9% +/- 11.6% at 1 year and 60.3% +/- 19.0% at 3 years. The results suggest that thrombosed vein grafts initially salvaged with thrombolysis and revision do not have a favorable long-term patency, and that a premium must be placed on the detection of the failing vein graft before thrombosis.
authors.affiliation: Department of Surgery and Radiology, Brigham and Women's Hospital, Boston, MA 02115.
authors.forename: M
authors.initials: M
authors.lastname: Belkin
authors.forename: M C
authors.initials: MC
authors.lastname: Donaldson
authors.forename: A D
authors.initials: AD
authors.lastname: Whittemore
authors.forename: J F
authors.initials: JF
authors.lastname: Polak
authors.forename: C J
authors.initials: CJ
authors.lastname: Grassi
authors.forename: D P
authors.initials: DP
authors.lastname: Harrington
authors.forename: J A
authors.initials: JA
authors.lastname: Mannick
mesh_terms: D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000453:epidemiology; D007866:Leg / Q000098:blood supply*; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013927:Thrombosis / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors; D014680:Veins / Q000637:transplantation*
chemical_list: D005343:Fibrinolytic Agents